reports
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
Hyloris Reports 1H24 preliminary results, auditor review ongoing
Hyloris reported preliminary 1H24 results with total revenues of € 4.6m (1H23: € 2.3m), which include a € 2.1m milestone payment for the launch of Maxigesic IV in the US. While a specific cash runway was not provided, the company believes it's well capitalised to fund R&D for existing products, but will require additional funding to commercialise its near-term cardiology products in the US. We reiterate our € 5 TP and Hold rating.
Galapagos verwelkomt Oleg Nodelman in haar Raad van Bestuur om strateg...
Galapagos verwelkomt Oleg Nodelman in haar Raad van Bestuur om strategische groei te ondersteunen Mechelen, België; 7 oktober 2024, 7:00 CET - Galapagos NV (Euronext & NASDAQ: GLPG), kondigde vandaag de benoeming aan, via coöptatie, van Oleg Nodelman, als Niet-Uitvoerend, Niet-Onafhankelijk Bestuurder in haar Raad van Bestuur, met ingang van 7 oktober 2024. De heer Nodelman vervangt de heer Dan G. Baker die op 6 oktober 2024 is afgetreden. De toevoeging van de heer Nodelman markeert een belangrijke stap in de inspanningen van Galapagos om de dialoog met aandeelhouders te versterken en de u...
Galapagos welcomes Oleg Nodelman to its Board of Directors to support ...
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos’ ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelera...
Galapagos receives transparency notification from EcoR1 Capital
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 26 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified us that EcoR1 Capital LLC holds 7,094,049 of Galapagos’ voting rights, consisting of 6,939,043 ordinary shares and 155,006 American Depository Receipts, further to a conversio...
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
Galapagos ontvangt transparantieverklaring van EcoR1 Capital Mechelen, België; 30 september 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van EcoR1 Capital LLC. Overeenkomstig de Belgische transparantiewetgeving1, heeft Galapagos op 26 september 2024 een kennisgeving van belangrijke deelneming ontvangen in naam van Dhr. Oleg Nodelman en EcoR1 Capital LLC, waarin staat dat EcoR1 Capital LLC 7.094.049 stemrechten in Galapagos bezit, bestaande uit 6.939.043 aandelen en 155.006 American Deposito...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Hyloris Hyloris' partner AFT out licences Maxigesic IV in China
Hyloris announced that its partner AFT Pharmaceuticals has signed an exclusive licensing agreement for Maxigesic IV (1000mg paracetamol with 300mg ibuprofen) for China with a subsidiary of Xizang Weixinkang Pharmaceutical. Hyloris will be eligible for a share of the $300K upfront received by AFT, as well as milestones and royalties. Details on the development plans in China have not been disclosed, though we believe a local trial would likely be required to gain approval by the Chinese NMPA (nat...
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
Life Sciences Conference 26.09.2024
This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX
Galapagos receives transparency notification from EcoR1 Capital
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified that EcoR1 Capital LLC holds 6,713,553 of Galapagos’ voting rights, consisting of 839,388 ordinary shares and 5,874,165 American Depository Receipts, further to an acquisiti...
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
Galapagos ontvangt transparantieverklaring van EcoR1 Capital Mechelen, België; 16 september 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van EcoR1 Capital, LLC. Overeenkomstig de Belgische transparantiewetgeving1, heeft Galapagos op 13 september 2024 een kennisgeving van belangrijke deelneming ontvangen in naam van Dhr. Oleg Nodelman en EcoR1 Capital LLC, waarin staat dat EcoR1 Capital LLC 6.713.553 stemrechten in Galapagos bezit, bestaande uit 839.388 aandelen en 5.874.165 American Dep...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
Galapagos receives transparency notification from FMR LLC
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 August 2024 from FMR LLC, who notified that it holds 2,687,116 of Galapagos’ voting rights, consisting of 2,686,016 ordinary shares and 1,100 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Man...
Galapagos ontvangt transparantieverklaring van FMR LLC
Galapagos ontvangt transparantieverklaring van FMR LLC Mechelen, België; 3 september 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van FMR LLC. Overeenkomstig de Belgische transparantiewetgeving1, heeft Galapagos op 30 augustus 2024 een kennisgeving van belangrijke deelneming ontvangen van FMR LLC, waarin staat dat zij 2.687.116 stemrechten in Galapagos bezit, bestaande uit 2.686.016 aandelen en 1.100 gelijkgestelde financiële instrumenten. FMR LLC controleert beleggingsfondsen Fidelity Ma...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
Galapagos FIRST LOOK: ATALANTA-1 to kick off in the US
Galapagos has obtained IND clearance to initiate its ATALANTA-1 study with GLPG5101 for r/r NHL in the US. The study is already ongoing in Europe, and Galapagos recently presented encouraging data at EHA with solid outcomes generally in line with Yescarta and outperforming in FL. Looking ahead, we anticipate additional data from Galapagos' CAR-T programs (likely at ASH) could provide further validation as the dataset matures. We reiterate our € 50 TP and Buy rating.
Galapagos announces FDA clearance of IND application for Phase 1/2 ATA...
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). G...
Galapagos receives transparency notification from FMR LLC
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, who notified that it holds 3,696,750 of Galapagos’ voting rights, consisting of 3,693,550 ordinary shares and 3,200 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM LLC, Fidelity ...
Galapagos ontvangt transparantieverklaring van FMR LLC
Galapagos ontvangt transparantieverklaring van FMR LLC Mechelen, België; 20 augustus 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van FMR LLC. Overeenkomstig de Belgische transparantiewetgeving1, heeft Galapagos op 16 augustus 2024 een kennisgeving van belangrijke deelneming ontvangen van FMR LLC, waarin staat dat zij 3.696.750 stemrechten in Galapagos bezit, bestaande uit 3.693.550 aandelen en 3.200 gelijkgestelde financiële instrumenten. FMR LLC controleert beleggingsfondsen Fidelity Man...
- Hilde Van Boxstael
- Thomas Couvreur
- Thomas Vranken
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.